A long PCR assay to distinguish CYP2D6*5 and a novel CYP2D6 mutant allele associated with an 11-kb EcoRI haplotype

Clinica Chimica Acta

Volumn 347, Issue 1-2, 2004, Pages 217-221

  Ishiguro, Akihiro ^a   Kubota, Takahiro ^a   Sasaki, Hiroshi ^b   Iga, Tatsuji ^a  

^a UNIVERSITY OF TOKYO HOSPITAL   (Japan)

^b SRL INC   (Japan)

Author keywords

CYP; CYP2D6*5; cytochrome P450; EcoRI; Haplotype; Japanese; Long PCR; PCR; polymerase chain reaction; restriction fragment length polymorphism; RFLP

Indexed keywords

CYTOCHROME P450 2D6; GENOMIC DNA;

ADULT; ALLELE; ARTICLE; CONTROLLED STUDY; ETHNIC GROUP; FEMALE; GENE AMPLIFICATION; GENE IDENTIFICATION; HAPLOTYPE; HUMAN; JAPAN; MALE; MUTANT; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

ADULT; ALLELES; BASE SEQUENCE; CYTOCHROME P-450 CYP2D6; DEOXYRIBONUCLEASE ECORI; DNA; DNA PRIMERS; FEMALE; GENOTYPE; HAPLOTYPES; HUMANS; JAPAN; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MUTATION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 4143118954     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cccn.2004.04.020     Document Type: Article

References (15)

1. Cholerton S., Daly A.K., Idle J.R. The role of individual human cytochromes P450 in drug metabolism and clinical response. Trends Pharmacol. Sci. 13:1992;434-439
2. Meyer U.A. Pharmacogenetics and adverse drug reactions. Lancet. 356:2000;1667-1671
3. Human Cytochrome P450 (CYP) Allele Nomenclature Committee. CYP2D6 allele nomenclature. http://www.immol/l.ki.se/CYPalleles/cyp2d6.htm (Accessed April 11, 2004).
4. Kubota T., Yamaura Y., Ohkawa N., Hara H., Chiba K. Frequencies of CYP2D6 mutant alleles in a normal Japanese population and metabolic activity of dextromethorphan O-demethylation in different CYP2D6 genotypes. Br. J. Clin. Pharmacol. 50:2000;31-34
5. Garcia-Barceló M., Chow L.Y., Chiu H.F.K., et al. Genetic analysis of the CYP2D6 Locus in a Hong Kong Chinese population. Clin. Chem. 46:2000;18-23
6. Steen V.M., Andreassen O.A., Daly A.K., et al. Detection of the poor metabolizer-associated CYP2D6 (D) gene deletion allele by long-PCR technology. Pharmacogenetics. 5:1995;215-223
7. McLellan R.A., Oscarson M., Seidegard J., Evans D.A.P., Ingelman-Sundberg M. Frequent occurrence of CYP2D6 gene duplication in Saudi Arabians. Pharmacogenetics. 7:1997;187-191
8. Ishiguro A., Kubota T., Sasaki H., Yamada Y., Iga T. Common mutant alleles of CYP2D6 causing the defect of CYP2D6 enzyme activity in a Japanese population. Br. J. Clin. Pharmacol. 55:2003;414-415
9. Mitsunaga Y., Kubota T., Ishiguro A., et al. Frequent occurrence of CYP2D6*10 duplication allele in a Japanese population. Mutat. Res. 505:2002;83-85
10. Harada S., Tachikawa H., Kawanishi Y. Gultathione S-transferase M1 gene deletion may be associated with susceptibility to certain forms of schizophrenia. Biochem. Biophys. Res. Commun. 281:2001;267-271
11. Lundqvist E., Johansson I., Ingelman-Sundberg M. Genetic mechanisms for duplication and multiduplication of the human CYP2D6 gene and methods for detection of duplicated CYP2D6 genes. Gene. 226:1999;327-338
12. Steen V.M., Molven A., Aarskog N.K., Gulbrandsen A.K. Homologous unequal cross-over involving a 2.8 kb direct repeat as a mechanism for the generation of allelic variants of the human cytochrome P450 CYP2D6 gene. Hum. Mol. Genet. 4:1995;2251-2257
13. Molven A., Steen V.M. A retroviral element in the human CYP2D gene cluster. Pharmacogenetics. 375:1996;375-377
14. Fukuda T., Nishida Y., Imaoka S., et al. The decreased in vivo clearance of CYP2D6 substrates by CYP2D6*10 might be caused not only the low-expression but also by low affinity of CYP2D6. Arch. Biochem. Biophys. 380:2000;303-308
15. Zanger U.M., Fischer J., Raimundo S., et al. Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6. Pharmacogenetics. 11:2001;573-585